Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2007 2
2008 6
2009 2
2010 5
2011 5
2012 5
2013 11
2014 7
2015 8
2016 14
2017 9
2018 8
2019 12
2020 10
2021 24
2022 22
2023 17
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Results by year

Filters applied: . Clear all
Page 1
Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Taki M, et al. Among authors: hamanishi j. Clin Cancer Res. 2021 Sep 1;27(17):4669-4679. doi: 10.1158/1078-0432.CCR-20-4459. Epub 2021 Apr 7. Clin Cancer Res. 2021. PMID: 33827891 Review.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A, Suzuki H, Hosoe Y, Furutake Y, Taki M, Abiko K, Yamaguchi K, Nakai H, Baba T, Matsumura N, Yoshizawa A, Ueno H, Mandai M. Ukita M, et al. Among authors: hamanishi j. JCI Insight. 2022 Jun 22;7(12):e157215. doi: 10.1172/jci.insight.157215. JCI Insight. 2022. PMID: 35552285 Free PMC article.
B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T, Murakami R, Hamanishi J, Tanigaki K, Hosoe Y, Mise N, Takamatsu S, Mise Y, Ukita M, Taki M, Yamanoi K, Horikawa N, Abiko K, Yamaguchi K, Baba T, Matsumura N, Mandai M. Miyamoto T, et al. Among authors: hamanishi j. Cancer Immunol Res. 2022 Jan;10(1):56-69. doi: 10.1158/2326-6066.CIR-21-0407. Epub 2021 Nov 19. Cancer Immunol Res. 2022. PMID: 34799346 Free PMC article.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Free PMC article. Clinical Trial.
Immune checkpoint inhibition in ovarian cancer.
Hamanishi J, Mandai M, Konishi I. Hamanishi J, et al. Int Immunol. 2016 Jul;28(7):339-48. doi: 10.1093/intimm/dxw020. Epub 2016 Apr 7. Int Immunol. 2016. PMID: 27055470 Review.
Reply to D.-C. Mo et al.
Hamanishi J. Hamanishi J. J Clin Oncol. 2022 Feb 10;40(5):523-524. doi: 10.1200/JCO.21.02636. Epub 2021 Dec 10. J Clin Oncol. 2022. PMID: 34890244 No abstract available.
Cancer immunotherapies targeting the PD-1 signaling pathway.
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Iwai Y, et al. Among authors: hamanishi j. J Biomed Sci. 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9. J Biomed Sci. 2017. PMID: 28376884 Free PMC article. Review.
141 results